Press Releases Cumberland Pharmaceuticals Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.695 ^USD	-3.69%		+4.63%	-5.40%

Mar. 13	Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.	CI
Mar. 05	Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS	Apr. 02	PR
Cumberland Pharmaceuticals : CEO Message	Mar. 12	PU
Cumberland Pharmaceuticals : CEO Message	Mar. 05	PU
Cumberland: Q4 Earnings Snapshot	Mar. 05	AQ
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results	Mar. 05	PR
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS	Feb. 27	PR
Cumberland: Q3 Earnings Snapshot	Nov. 07	AQ
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results	Nov. 07	PR
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS	23-10-31	PR
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE	23-10-10	PR
Cumberland Pharmaceuticals : CEO Message	23-08-14	PU
Cumberland: Q2 Earnings Snapshot	23-08-08	AQ
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023	23-08-08	PR
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS	23-08-01	PR
Cumberland Pharmaceuticals : The FIGHT DMD Trial	23-07-25	PU
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS	23-06-26	PR
CUMBERLAND PHARMACEUTICALS INC : Other Events (form 8-K)	23-06-22	AQ
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS	23-05-23	PR
CUMBERLAND PHARMACEUTICALS INC : Other Events (form 8-K)	23-05-16	AQ
CUMBERLAND PHARMACEUTICALS - CALDOLOR NOW FDA APPROVED FOR TREATMENT OF FEVER AND PAIN IN INFANTS	23-05-16	AQ

No results for this search